{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:37:49Z","timestamp":1791999469284,"version":"4.4.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Since its release in 2014, collagenase clostridium histolyticum (CCH) has become the most commonly used injectable therapy for Peyronie\u2019s disease (PD). While some studies have suggested modest improvements in curvature with use of CCH, others have found more significant gains.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>To determine predictors of improved curvature in men with PD treated with CCH.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A prospective, sequential database has been maintained of all men with PD undergoing CCH injections since 2014. Clinical characteristics and responses to standardized and nonstandardized questionnaires were collected at baseline, during, and after treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Outcomes<\/jats:title>\n                  <jats:p>Change in curvature was assessed using the \u201cMost Recent\u201d curvature assessment, and statistical analyses were performed to identify factors that correlated with greater curve improvements.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 826 men underwent at least one CCH series and comprise the current cohort. Univariate analysis demonstrated associations between greater curvature improvements in patients with more severe baseline curvature (0.5\u00b0 greater improvement per increase in 1\u00b0 baseline), hourglass deformities (3-10\u00b0 greater improvement among moderate\/severe men), number of CCH series administered (0-4\u00b0 per series), strong nocturnal erections (11\u00b0 higher), greater frequency of intercourse (0.6\u00b0 per intercourse attempt per month), greater bother and psychological impact (as assessed by the Peyronie\u2019s Disease Questionnaire), and those who used RestoreX (5-20\u00b0 depending on test). Worse outcomes were observed among men who self-reported decreased motivation (7\u00b0) as well as those with pure lateral curvatures (11\u00b0). Men who experienced hematomas, a popping sensation, and those with rapid detumescence during treatment also had more significant improvements in curvature (5\u00b0). On multivariate analysis, baseline curvature, lateral curve direction, hourglass\/indentation deformities, RestoreX use, and suspected controlled penile fracture remained independently associated with better outcomes. Of all the factors assessed, RestoreX use was associated with the largest degree of improvement.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Implications<\/jats:title>\n                  <jats:p>These findings highlight several potential predictors of improved outcomes with CCH, which may be utilized by providers to help counsel patients deciding on medical versus surgical treatment of PD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Strengths and Limitations<\/jats:title>\n                  <jats:p>The strengths include the largest single-center prospective database of PD patients undergoing CCH published to date and use of objective and validated instruments to track PD outcomes. Limitations include the single-center nature, diverse patient cohort, and change in CCH technique over time.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Several baseline and treatment-related factors correlate with CCH outcomes. These data may assist both patients and providers as they relate to patient selection and counseling. The data also suggest the importance of patient motivation and active participation during the treatment course.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jsxmed\/qdaf213","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T05:55:37Z","timestamp":1755237337000},"page":"1799-1807","source":"Crossref","is-referenced-by-count":3,"title":["Factors associated with improved curvature outcomes with collagenase <i>clostridium histolyticum<\/i> for Peyronie\u2019s disease: results from a large prospective series"],"prefix":"10.1093","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0459-534X","authenticated-orcid":false,"given":"Ellen M","family":"Cahill","sequence":"first","affiliation":[{"name":"Department of Urology, Yale University School of Medicine , New Haven, CT 06510 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Landon","family":"Trost","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, Brigham Young University , Provo, UT 84602 ,","place":["United States"]},{"name":"Male Fertility and Peyronie\u2019s Clinic , Orem, UT 84057 ,","place":["United States"]},{"name":"CURE PD , Orem, UT 84057 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"issue":"7","key":"2025100504565648300_ref1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1046\/j.1464-4096.2001.02436.x","article-title":"The prevalence of Peyronie's disease: results of a large survey","volume":"88","author":"Schwarzer","year":"2001","journal-title":"BJU Int"},{"issue":"2","key":"2025100504565648300_ref2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150157","article-title":"The prevalence of Peyronie's disease in the United States: a population-based study","volume":"11","author":"Stuntz","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"2025100504565648300_ref3","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/S0022-5347(17)37988-0","article-title":"The incidence of Peyronie's disease in Rochester, Minnesota, 1950 through 1984","volume":"146","author":"Lindsay","year":"1991","journal-title":"J Urol"},{"key":"2025100504565648300_ref4","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/282503","article-title":"A population-based study of Peyronie's disease: prevalence and treatment patterns in the United States","volume":"2011","author":"Dibenedetti","year":"2011","journal-title":"Adv Urol"},{"issue":"5","key":"2025100504565648300_ref5","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/sj.ijir.3900727","article-title":"Prevalence of Peyronie's disease in men over 50-y-old from Southern Brazil","volume":"13","author":"Rhoden","year":"2001","journal-title":"Int J Impot Res"},{"issue":"1","key":"2025100504565648300_ref6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0022-5347(01)65367-9","article-title":"Fibrin deposition in Peyronie's disease plaque","volume":"157","author":"Somers","year":"1997","journal-title":"J Urol"},{"issue":"8","key":"2025100504565648300_ref7","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1111\/j.1743-6109.2008.00883.x","article-title":"Impact of Peyronie's disease on sexual and psychosocial functioning: qualitative findings in patients and controls","volume":"5","author":"Rosen","year":"2008","journal-title":"J Sex Med"},{"issue":"3","key":"2025100504565648300_ref8","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1743-6109.2012.02999.x","article-title":"Psychological impact of Peyronie's disease: a review","volume":"10","author":"Nelson","year":"2013","journal-title":"J Sex Med"},{"issue":"8","key":"2025100504565648300_ref9","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1111\/j.1743-6109.2008.00895.x","article-title":"The chronology of depression and distress in men with Peyronie's disease","volume":"5","author":"Nelson","year":"2008","journal-title":"J Sex Med"},{"issue":"2","key":"2025100504565648300_ref10","article-title":"Treatment patterns and healthcare outcomes with collagenase clostridium histolyticum vs surgery in Peyronie's disease: a retrospective claims database analysis","volume":"9","author":"Trost","year":"2021","journal-title":"Sex Med"},{"issue":"1","key":"2025100504565648300_ref11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","article-title":"Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies","volume":"190","author":"Gelbard","year":"2013","journal-title":"J Urol"},{"issue":"1","key":"2025100504565648300_ref12","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/jsm.12731","article-title":"Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie's disease: a phase 3 open-label study","volume":"12","author":"Levine","year":"2015","journal-title":"J Sex Med"},{"issue":"6","key":"2025100504565648300_ref13","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1016\/j.juro.2012.01.032","article-title":"Phase 2b study of the clinical efficacy and safety of collagenase clostridium histolyticum in patients with Peyronie disease","volume":"187","author":"Gelbard","year":"2012","journal-title":"J Urol"},{"issue":"6","key":"2025100504565648300_ref14","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.jsxm.2019.03.007","article-title":"Efficacy of combined collagenase clostridium histolyticum and RestoreX penile traction therapy in men with Peyronie's disease","volume":"16","author":"Alom","year":"2019","journal-title":"J Sex Med"},{"key":"2025100504565648300_ref15","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2022.09.017","article-title":"Improved Peyronie's disease curvature outcomes using a novel collagenase administration protocol","volume":"170","author":"Flores","year":"2022","journal-title":"Urology."},{"issue":"4","key":"2025100504565648300_ref16","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/bju.14410","article-title":"Predictors of treatment success after collagenase clostridium histolyticum injection for Peyronie's disease: development of a nomogram from a multicentre single-arm, non-placebo controlled clinical study","volume":"122","author":"Cocci","year":"2018","journal-title":"BJU Int"},{"issue":"11","key":"2025100504565648300_ref17","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/j.jsxm.2022.08.001","article-title":"Predictors of curvature improvement in men with Peyronie's disease treated with intralesional collagenase clostridium histolyticum","volume":"19","author":"Flores","year":"2022","journal-title":"J Sex Med"},{"key":"2025100504565648300_ref18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.urology.2017.04.045","article-title":"Self-reported clinical meaningfulness early in the treatment course predicts objective outcomes in men undergoing collagenase clostridium histolyticum injections for Peyronie disease","volume":"106","author":"Ziegelmann","year":"2017","journal-title":"Urology"},{"issue":"4","key":"2025100504565648300_ref19","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.sxmr.2019.05.001","article-title":"Discontinuation from collagenase clostridium histolyticum therapy for Peyronie's disease: review and single-Center cohort analysis","volume":"7","author":"Amighi","year":"2019","journal-title":"Sex Med Rev"},{"issue":"3","key":"2025100504565648300_ref20","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1097\/JU.0000000000004072","article-title":"Creation of a novel classification system (PTNM) for Peyronie's disease and penile curvature using evidence-based criteria","volume":"212","author":"Trost","year":"2024","journal-title":"J Urol"},{"key":"2025100504565648300_ref21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.urology.2018.06.003","article-title":"Plaque calcification: an important predictor of collagenase clostridium histolyticum treatment outcomes for men with Peyronie's disease","volume":"119","author":"Wymer","year":"2018","journal-title":"Urology"},{"key":"2025100504565648300_ref22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.urology.2019.01.055","article-title":"Safety and efficacy of collagenase clostridium histolyticum in Peyronie's disease men with ventral curvatures","volume":"129","author":"Alom","year":"2019","journal-title":"Urology"},{"issue":"2","key":"2025100504565648300_ref23","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/jsxmed\/qdad167","article-title":"Outcomes of collagenase clostridium histolyticum in men with ventral curvatures: an updated series","volume":"21","author":"Larson","year":"2024","journal-title":"J Sex Med"},{"issue":"12","key":"2025100504565648300_ref24","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1093\/jsxmed\/qdae134","article-title":"An illustrated description of a modified collagenase clostridium histolyticum protocol for Peyronie's disease","volume":"21","author":"Trost","year":"2024","journal-title":"J Sex Med"},{"issue":"4","key":"2025100504565648300_ref25","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/bju.13096","article-title":"Clinical efficacy of collagenase clostridium histolyticum in the treatment of Peyronie's disease by subgroup: results from two large, double-blind, randomized, placebo-controlled, phase III studies","volume":"116","author":"Lipshultz","year":"2015","journal-title":"BJU Int"},{"issue":"1","key":"2025100504565648300_ref26","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41443-020-00383-7","article-title":"Conservative management of suspected fractures in men undergoing collagenase clostridium histolyticum for Peyronie's disease is not associated with worsening of erectile function","volume":"34","author":"Sharma","year":"2022","journal-title":"Int J Impot Res"},{"issue":"10","key":"2025100504565648300_ref27","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/j.jsxm.2018.08.012","article-title":"Sildenafil 25 mg ODT + collagenase clostridium hystoliticum vs collagenase clostridium hystoliticum alone for the Management of Peyronie's disease: a matched-pair comparison analysis","volume":"15","author":"Cocci","year":"2018","journal-title":"J Sex Med"},{"issue":"4","key":"2025100504565648300_ref28","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.jsxm.2021.02.002","article-title":"Predictors of depression in men with Peyronie's disease seeking evaluation","volume":"18","author":"Punjani","year":"2021","journal-title":"J Sex Med"},{"issue":"3","key":"2025100504565648300_ref29","doi-asserted-by":"publisher","first-page":"290","DOI":"10.21037\/tau.2016.05.14","article-title":"Psychological aspects of Peyronie's disease","volume":"5","author":"Terrier","year":"2016","journal-title":"Transl Androl Urol"},{"issue":"2","key":"2025100504565648300_ref30","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.juro.2013.01.090","article-title":"Bother and distress associated with Peyronie's disease: validation of the Peyronie's Disease Questionnaire","volume":"190","author":"Hellstrom","year":"2013","journal-title":"J Urol"},{"key":"2025100504565648300_ref31","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.urology.2020.07.048","article-title":"Safety and efficacy of collagenase clostridium histolyticum in the treatment of acute phase Peyronie's disease: a multi-institutional analysis","volume":"145","author":"Nguyen","year":"2020","journal-title":"Urology"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/22\/10\/1799\/64054902\/qdaf213.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/22\/10\/1799\/64054902\/qdaf213.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T08:57:05Z","timestamp":1759654625000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/22\/10\/1799\/8235645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":31,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,8,15]]},"published-print":{"date-parts":[[2025,10,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jsxmed\/qdaf213","relation":{},"ISSN":["1743-6095","1743-6109"],"issn-type":[{"value":"1743-6095","type":"print"},{"value":"1743-6109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,8,15]]}}}